stockrowLeMaitre Vascular, Inc.
LMAT Healthcare Medical Instruments & Supplies
LeMaitre Vascular, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $249.6 million, up 13.5% from fiscal 2024.
- Revenue
- +11.3%
- EPS
- −14.3%
- Free cash flow
- −25.8%
- Total debt
- +0.53%
Quarter to September 2026, against a year earlier
Follow LMAT
Alert me
LeMaitre Vascular, Inc. (LMAT) EBITDA
LeMaitre Vascular, Inc.'s EBITDA for fiscal 2025 was $79.2M, up 27.9% from $61.9M in fiscal 2024. Over the twelve months to 30 June 2026 it was $88.7M. Over the past ten years it has ranged from $14.9M (fiscal 2015) to $79.2M (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 3 consecutive fiscal years. LeMaitre Vascular, Inc. ranks 22nd of 47 Medical Instruments & Supplies companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $79.2M | 27.90% |
| FY2024 | $61.9M | 33.96% |
| FY2023 | $46.2M | 27.48% |
| FY2022 | $36.3M | (23.65%) |
| FY2021 | $47.5M | 27.73% |
| FY2020 | $37.2M | 39.79% |
| FY2019 | $26.6M | (18.24%) |
| FY2018 | $32.5M | 29.31% |
| FY2017 | $25.2M | 26.25% |
| FY2016 | $19.9M | 33.68% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $23.3M | 12.92% |
| Mar 2026 | $20.6M | (4.79%) |
| Dec 2025 | $21.7M | (6.43%) |
| Sep 2025 | $23.1M | 21.75% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| XRAY DENTSPLY SIRONA Inc. compare | $408.0M |
| STVN Stevanato Group S.p.A. compare | $351.1M |
| LMAT LeMaitre Vascular, Inc. | $88.7M |
| WRBY Warby Parker Inc. compare | $59.0M |
| ATRC AtriCure, Inc. compare | $34.2M |
| AZTA Azenta, Inc. compare | $28.1M |
| STAA STAAR Surgical Company compare | $23.2M |
| PLSE Pulse Biosciences, Inc compare | −$82.0M |
| KMTS Kestra Medical Technologies, Ltd. compare | −$133.4M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on LMAT
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement